⌘K

08:49:02·7d

SECFiling

SEC Form DEFA14A filed by Vir Biotechnology Inc.

VIR· Vir Biotechnology Inc.

Health Care

Original source

Companies

VIR
Vir Biotechnology Inc.
Health Care

Recent analyst ratings

Feb 24UpdateRaymond James$19.00
Sep 3UpdateEvercore ISI$12.00
Aug 27UpdateBofA Securities$14.00
Jan 29UpdateJP Morgan$9.00
Sep 8UpdateBofA Securities$14.00
Mar 6UpdateJP Morgan$34.00

Related

PR7h
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
SEC7d
SEC Form DEF 14A filed by Vir Biotechnology Inc.
PR7d
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
PR10d
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SEC13d
SEC Form 8-K filed by Vir Biotechnology Inc.
INSIDER16d
SEC Form 4 filed by De Backer Marianne
INSIDER21d
SEC Form 4 filed by Sato Vicki L
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Vir Biotechnology Inc.